FDA seeks pain patients’ perspectives
The U.S. Food and Drug Administration (FDA) is asking pain patients to share “perspectives on the impacts of chronic pain, views on treatment approaches for chronic pain, and challenges or barriers to accessing treatments.”
According to information posted on FDA’s website, the agency is particularly interested in hearing from “patients who experience chronic pain that is managed with analgesic medications such as opioids, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants; other medications; and non-pharmacologic interventions or therapies.”
FDA held a public hearing on July 9 to gather feedback, but will accept online or mailed comments through Sept. 10.
